George D. Yancopoulos - Articles and news items

Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction

Industry news / 16 October 2013 / Sanofi

Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe…


Sanofi and Regeneron announce patient enrollment in two Phase 3 trials with sarilumab in RA

Industry news, News / 15 May 2013 / Sanofi

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials…


Sanofi and Regeneron report positive proof-of-concept data for Dupilumab

Industry news, News / 2 March 2013 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab…


ZALTRAP® (aflibercept) approved in the EU

Industry news, News / 5 February 2013 / Sanofi

First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen…


ZALTRAP® receives CHMP positive opinion in the European Union for previously treated mCRC

Industry news, News / 16 November 2012 / Sanofi

“We are pleased that CHMP has supported our ZALTRAP application…”

Sanofi and Regeneron report positive Phase 2b trial results with sarilumab in rheumatoid arthritis

Industry news, News / 12 July 2011 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials…

ZALTRAP™ (aflibercept) significantly improved survival in previously treated metastatic colorectal cancer patients

Industry news, News / 6 June 2011 / Sanofi

Data will be presented at the ESMO World Congress on Gastrointestinal Cancer…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...